The Magazine for Sleep Professionals
Friday, May 8, 2026
Eli Lilly and Company announced the U.S. Food and Drug Administration (FDA) approved Zepbound® (tirzepatide) as the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity.1 Zepbound may help adults with moderate-to-severe obstructive sleep apnea and obesity improve their sleep disorder. It should be used with […]
P4 medicine is an evolving approach to personalized medicine that involves four key elements of care: 1) predicting who will develop disease and comorbidities, 2) preventing rather than reacting to disease, 3) personalizing diagnosis and treatment, 4) having patients participate in their own care.1 This approach is gaining traction in […]
A pioneering study by sleep researchers at Stanford University, in collaboration with SoundHealth Inc., explores how smartphone facial scans powered by artificial intelligence can analyze facial structures linked to sleep disorders. This innovative approach uses smartphone cameras to assess craniofacial and maxillofacial features, shedding light on potential anatomical contributors to […]
LivaNova PLC, a market-leading medical technology company, today announced that it met the primary endpoints for its OSPREY randomized controlled trial (RCT), Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation. Together with its safety endpoints, the RCT achieved statistical significance of its primary endpoint responder rates1,2 between the treatment […]
React Health has announced the latest addition to its Rio II family of masks: the Rio II Full Face Mask, which is now available. Designed to enhance patient comfort and compliance with sleep therapy, the Rio II offers a cost-competitive alternative to many leading masks on the market without compromising […]
Ognomy Inc., a trailblazing telemedicine platform dedicated to transforming sleep apnea care, proudly announces the successful completion of its Series Seed Preferred financing round, bringing its total funding to over $6.8 million. This funding milestone coincides with the company surpassing 11,000 patients served, marking a pivotal moment in its mission […]
EnsoData and Nonin partner to address the underserved and undiagnosed sleep apnea patient population with a collaborative home sleep apnea testing approach. The partnership will combine the recently FDA-cleared EnsoSleep PPG software as a medical device (SaMD) algorithm with Nonin’s WristOx2® Model 3150 reusable wrist-worn device, offering sleep labs an […]
There has been an increasing number of studies looking at orofacial myofunctional therapy (OMT) as a promising adjunctive treatment for obstructive sleep apnea (OSA).1 OMT essentially helps the patient to retrain the muscles around the face, mouth, and tongue to establish correct oral rest posture and functioning of the oral […]
Incannex Healthcare Inc., a pharmaceutical company developing unique medicinal cannabinoid pharmacotherapies and psychedelic medicine therapies, is pleased to announce that patient dosing has commenced in the Company’s Phase 2/3 clinical trial to assess the safety and efficacy of IHL-42X in patients with obstructive sleep apnea (OSA). IHL-42X is the Company’s […]
IntelliPAP™ is a new optional tool for physicians to use in noninvasive ventilation for patients with respiratory insufficiency and obstructive sleep apnea (OSA). This innovative device automatically adjusts the positive end-expiratory pressure (PEEP) levels in response to sleep-disordered breathing (SDB) events. To enhance safety, clinicians can set minimum and maximum […]
